In essence, biotechnology is the application of biology to develop products and technologies that contribute to improving human life and protecting the environment. It uses cellular, molecular, and biomolecular processes to improve the health of planet Earth and improve lives.
Bread and cheese, both essential food items, have been produced using biotechnology for the last 6000 years. Our modern dairy products, butter, and curds are preserved by these methods.
As technology improves, biotechnology provides breakthrough products and technologies to not just reduce our carbon footprint, but also to feed the hungry, utilize cleaner energy, and produce new safe, and efficient industrial products.
It is very different to invest in biotech than in any other industry. Because biotech companies conduct extensive research, development, and testing, their operating costs tend to be high. Furthermore, regulatory barriers can inhibit the introduction of new products; for instance, some countries prohibit GM crops, and approval from US FDA (Food and Drug Administration) is costly and lengthy.
To be specific, biotech investments are considered to be very risky.
A biotech investor does not have to own stock in a specific company in order to invest. You can invest in biotech by purchasing an exchange-traded fund (ETF). From these funds, investors can invest in a wide variety of biotech companies in a single transaction. Here are some biotech stocks to buy you might consider.
aTyr Pharma Inc. (LIFE) shares were rising 13.88% to trade at $10.42 in pre-market at last check. LIFE’s stock gained 66.97% to close Monday’s session at $9.15. The stock volume remained 114.77 million shares, which was higher than the average daily volume of 2.47 million shares within the past 50 days. LIFE shares have risen by 154.87% over the last 12 months, and they have moved up by 66.67% in the past week. Over the past three months, the stock has gained 93.45%, while over the past six months, it has shed 88.27%. Further, the company has a current market of $156.83 million and its outstanding shares stood at 16.13 million.
Focusing on the company’s market volatility shows that it has a 1-Week Volatility index of 15.18%, and 6.94% for the month. This stock’s Average True Range (ATR) currently stands at 0.46, with the beta factor poised at 2.01. The indicator of Volatility helps exhibit the extent to which a stock is likely to plummet or climb when the rest of the market also dips or surges. If a stock has a beta score above 1, then its rate of volatility is high. Figures lower than 1, therefore, mean that the stock’s volatility at that particular moment is low.
At last check in pre-market trading, shares of Matinas BioPharma Holdings Inc. (MTNB) were up 8.57% at $1.14. MTNB’s stock closed the last session at $1.05, increasing 27.12% or $0.22. Shares of the company fluctuated between $0.89 and $1.10 throughout the day. The number of shares exchanged was 12.88 million, greater than the company’s 50-day daily volume of 1.15 million and higher than its Year to date volume of 2.6 million. In the past 12 months, the company’s stock has retreated 51.45%, and in the last one week, the stock has moved up 31.25%. For the last six months, the stock has lost a total of -13.22%, and over the last three months, the stock has increased by 17.96%. The stock has returned -22.79% so far this year.
Wall Street analysts tracking the Matinas BioPharma Holdings Inc. (AMEX: MTNB) stock on daily basis. Out of 5 analysts, 4 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT. Another 1 recommended that MTNB is a HOLD, while 0 rated it UNDERWEIGHT and the 0 recommended SELL. If we look at the broader picture, the above ratings give the stock an average analyst rating of 2.00.
BELLUS Health Inc. (BLU) shares have gained 0.42% at $4.80 in Tuesday’s premarket session. BELLUS Health Inc.’s stock added 21.94% to finish last trading session at $4.78. The stock recorded a trading volume of 38.2 million shares, which is below the average daily trading volume published for the last 50 days of 1.24 million shares. The shares of BELLUS Health Inc. have retreated 24.48% in the last five days; however, they have gained 40.59% over the last one month. The stock price has surged 37.75% over the last three months and has gained 106.03 percent so far this year. Additionally, it has a price to sales ratio stands at 24891.05.
BELLUS Health Inc.’s return on equity, or ROE, is -36.50%, compared to the industry average of -37.33% for Healthcare – Biotechnology. Although this indicates that blu uses its equity well, the metric will vary significantly depending on the industry.